@article{f3cd62d771894eb89436ab13aa0a1707,
title = "Itraconazole or amphotericin B for talaromycosis",
author = "Br{\"u}ggemann, \{Roger J.\} and \{Van De Veerdonk\}, \{Frank L.\} and Verweij, \{Paul E.\}",
note = "Funding Information: 1. Abuhelwa AY, Foster DJ, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modeling of itraconazole and hydroxy-itraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Anti-microb Agents Chemother 2015;59:5681-96. 2. Br{\"u}ggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48:1441-58. 3. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:807-25. 4. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. AIDSinfo 2017:T-10 (http://aidsinfo.nih.gov/contentfiles/ lvguidelines/adult\_oi.pdf).",
year = "2017",
month = oct,
day = "5",
doi = "10.1056/NEJMc1709123",
language = "English",
volume = "377",
pages = "1402--1403",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "14",
}